klacid i.v. infusioonilahuse kontsentraadi pulber
viatris sia - klaritromütsiin - infusioonilahuse kontsentraadi pulber - 500mg 1tk
fromilid õhukese polümeerikattega tablett
krka d.d. novo mesto - klaritromütsiin - õhukese polümeerikattega tablett - 500mg 14tk
fromilid õhukese polümeerikattega tablett
krka d.d. novo mesto - klaritromütsiin - õhukese polümeerikattega tablett - 250mg 14tk
daktarin suukaudne geel
johnson & johnson uab - mikonasool - suukaudne geel - 20mg 1g 40g 1tk
daktarin suukaudne geel
lex ano uab - mikonasool - suukaudne geel - 20mg 1g 40g 1tk
lunsumio
roche registration gmbh - mosunetuzumab - lümfoom, follikulaarne - antineoplastic agents, monoclonal antibodies - lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (fl) who have received at least two prior systemic therapies.
fugasol vet suukaudne lahus
cp-pharma handelsgesellschaft mbh - itrakonasool - suukaudne lahus - 10mg 1ml 25ml 1tk; 10mg 1ml 50ml 1tk
daktarin suukaudne geel
ideal trade links uab - mikonasool - suukaudne geel - 20mg 1g 40g 1tk
klacid 125 mg/5 ml suukaudse suspensiooni graanulid
ideal trade links uab - klaritromütsiin - suukaudse suspensiooni graanulid - 25mg 1ml 100ml 1tk
breyanzi
bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - antineoplastilised ained - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.